Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Nicotine from cigarette smoking and diet and Parkinson disease: a review.

Ma C, Liu Y, Neumann S, Gao X.

Transl Neurodegener. 2017 Jul 2;6:18. doi: 10.1186/s40035-017-0090-8. eCollection 2017. Review.

2.

Recent advances in treating Parkinson's disease.

Oertel WH.

F1000Res. 2017 Mar 13;6:260. doi: 10.12688/f1000research.10100.1. eCollection 2017. Review.

3.

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

Bordia T, Perez XA, Heiss J, Zhang D, Quik M.

Neurobiol Dis. 2016 Jul;91:47-58. doi: 10.1016/j.nbd.2016.02.019. Epub 2016 Feb 24.

4.

Genetic Factors for Enhancement of Nicotine Levels in Cultivated Tobacco.

Wang B, Lewis RS, Shi J, Song Z, Gao Y, Li W, Chen H, Qu R.

Sci Rep. 2015 Dec 2;5:17360. doi: 10.1038/srep17360.

5.

Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Sarter M, Albin RL, Kucinski A, Lustig C.

Exp Neurol. 2014 Jul;257:120-9. doi: 10.1016/j.expneurol.2014.04.032. Epub 2014 May 5. Review.

6.

A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking.

van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, van Laar T, Kromhout H, Vermeulen R.

PLoS One. 2014 Apr 30;9(4):e95297. doi: 10.1371/journal.pone.0095297. eCollection 2014.

7.

Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs.

Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM.

J Neurochem. 2014 Apr;129(2):315-27. doi: 10.1111/jnc.12616. Epub 2013 Dec 13.

8.

Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Quik M, Mallela A, Ly J, Zhang D.

Mov Disord. 2013 Sep;28(10):1398-406. doi: 10.1002/mds.25594. Epub 2013 Jul 8.

9.

Nicotine promotes survival of cells expressing amyloid precursor protein and presenilin: implication for Alzheimer's disease.

Brown D, Ramlochansingh C, Manaye KF, Tizabi Y.

Neurosci Lett. 2013 Feb 22;535:57-61. doi: 10.1016/j.neulet.2012.12.046. Epub 2013 Jan 8.

10.

Parkinson's disease.

Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA.

Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16. Review.

11.

A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.

Hill-Burns EM, Singh N, Ganguly P, Hamza TH, Montimurro J, Kay DM, Yearout D, Sheehan P, Frodey K, McLear JA, Feany MB, Hanes SD, Wolfgang WJ, Zabetian CP, Factor SA, Payami H.

Pharmacogenomics J. 2013 Dec;13(6):530-7. doi: 10.1038/tpj.2012.38. Epub 2012 Oct 2.

12.
13.

Nicotine as a potential neuroprotective agent for Parkinson's disease.

Quik M, Perez XA, Bordia T.

Mov Disord. 2012 Jul;27(8):947-57. doi: 10.1002/mds.25028. Epub 2012 Jun 12. Review.

14.

Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease.

Muñoz P, Huenchuguala S, Paris I, Cuevas C, Villa M, Caviedes P, Segura-Aguilar J, Tizabi Y.

Neurotox Res. 2012 Aug;22(2):177-80. doi: 10.1007/s12640-012-9326-7. Epub 2012 Apr 12. Erratum in: Neurotox Res. 2012 Oct;22(3):249.

15.

Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Hurley LL, Taylor RE, Tizabi Y.

Neurotox Res. 2012 Jan;21(1):57-69. doi: 10.1007/s12640-011-9275-6. Epub 2011 Sep 20. Review.

16.

Targeting nicotinic receptors for Parkinson's disease therapy.

Quik M, Bordia T, Huang L, Perez X.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8. Review.

17.

Toxic effects of low alcohol and nicotine combinations in SH-SY5Y cells are apoptotically mediated.

Ramlochansingh C, Taylor RE, Tizabi Y.

Neurotox Res. 2011 Oct;20(3):263-9. doi: 10.1007/s12640-011-9239-x. Epub 2011 Jan 8.

18.

Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.

Bencherif M, Lippiello PM, Lucas R, Marrero MB.

Cell Mol Life Sci. 2011 Mar;68(6):931-49. doi: 10.1007/s00018-010-0525-1. Epub 2010 Oct 15. Review.

19.

Gene-environment interactions in Parkinson's disease: the importance of animal modeling.

Horowitz MP, Greenamyre JT.

Clin Pharmacol Ther. 2010 Oct;88(4):467-74. doi: 10.1038/clpt.2010.138. Epub 2010 Sep 1. Review.

20.

Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.

Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, Marks MJ, Miwa JM, Lester HA.

J Neurosci. 2010 Jul 21;30(29):9877-89. doi: 10.1523/JNEUROSCI.2056-10.2010.

Supplemental Content

Support Center